Blepharophimosis Syndrome

Blepharophimosis Syndrome presents a complex challenge for therapeutics development. Protheragen is dedicated to advancing the science and preclinical practice in this area, offering a comprehensive suite of services from genetic diagnostics to cutting-edge therapeutics development.

Introduction to Blepharophimosis Syndrome

Blepharophimosis Syndrome (BPES) is a rare genetic disorder characterized by the underdevelopment of facial structures, primarily affecting the eyelids. This condition presents at birth and is hallmarked by a reduced horizontal opening of the eyelids (blepharophimosis), drooping of the upper eyelids (ptosis), increased distance between the inner corners of the eyes (telecanthus), and an upward fold of skin near the inner corner of the eye (epicanthus inversus). The syndrome can be classified into two types: Type I, which is associated with premature ovarian failure in females, and Type II, which presents only with the characteristic facial features.

Fig.1 Schematic diagram of the genomic location and protein structure of forkhead box L2 (FOXL2). (Méjécase, C., et al., 2021)

The genetic basis of Blepharophimosis Syndrome is well-established, with the majority of cases linked to mutations in the FOXL2 gene on chromosome 3q23. This gene encodes a transcription factor that plays a crucial role in the development of the eyelids and ovaries. Understanding the genetic mutations associated with Blepharophimosis Syndrome has paved the way for targeted diagnostics and therapeutics development.

Diagnostics Development for Blepharophimosis Syndrome

Therapeutics Development for Blepharophimosis Syndrome

Research is progressively exploring the use of gene therapy and other molecular interventions to correct the underlying genetic defects causing Blepharophimosis Syndrome. These involve potential CRISPR-based approaches to edit the FOXL2 gene directly or the development of small-molecule drugs that modulate gene expression pathways affected by FOXL2 mutations. Although still largely experimental, these methods signify a promising frontier in offering more comprehensive therapeutic options beyond traditional surgical approaches.

Our Services

By collaborating with leading experts in ophthalmology and endocrinology, Protheragen is able to provide specialized and high-quality diagnostics and therapeutic development services for Blepharophimosis Syndrome. By delivering a functional copy of the FOXL2 gene, our goal is to restore normal gene expression and improve the symptoms of the syndrome.

BS Target Identification and Validation Services

Protheragen provides specialized target identification and validation services to help clients identify and prioritize novel therapeutic targets for Blepharophimosis Syndrome, focusing on the molecular and cellular mechanisms driving the disorder's ocular and systemic manifestations. Our services include genomic and transcriptomic analysis of BS-relevant tissues (e.g., eyelid fibroblasts, lacrimal gland cells, ovarian tissue) and cell models, leveraging next-generation sequencing (NGS), quantitative PCR (qPCR), and single-cell RNA sequencing to identify dysregulated genes and pathways associated with FOXL2 and PITX2 mutations. We conduct functional validation studies using in vitro cell models (e.g., human eyelid fibroblasts, corneal epithelial cells, ovarian granulosa cells) and in vivo models to confirm the role of candidate targets in BS pathogenesis.

For example, our team can assess the impact of target modulation on eyelid fibroblast proliferation and differentiation—processes disrupted in BS due to FOXL2 mutations, as demonstrated in FOXL2 knockout mouse models—or evaluate the effect of target activation on lacrimal gland function to address epiphora. Additionally, Protheragen offers advanced bioinformatics analysis services to integrate genomic, transcriptomic, and phenotypic data, identifying key molecular networks and potential therapeutic targets that may have been overlooked. Our team can also validate targets using CRISPR-Cas9 gene editing, generating knockout or knock-in cell lines to assess the functional consequences of target dysregulation in BS. This rigorous target validation process ensures that clients focus their resources on targets with high translational potential, reducing the risk of late-stage preclinical failure and accelerating therapy development.

BS Preclinical Model Development and Characterization Services

Preclinical models that accurately recapitulate the phenotypic and molecular features of Blepharophimosis Syndrome are critical for evaluating therapeutic efficacy and safety, and Protheragen specializes in the development and characterization of physiologically relevant BS models. Our services include the development of in vitro models (e.g., patient-derived induced pluripotent stem cells (iPSCs), primary eyelid fibroblast cultures, lacrimal gland organoids) and in vivo models (e.g., FOXL2 knockout mice, zebrafish FOXL2 morphants) that mimic key BS manifestations, including blepharophimosis, ptosis, epicanthus inversus, telecanthus, lacrimal duct obstruction, and reproductive abnormalities.

For example, we can generate FOXL2 knockout mouse models that exhibit the classic ocular features of BS, including narrowed palpebral fissures, ptosis, and underdeveloped eyebrows, as well as systemic features such as hypogonadism and premature ovarian failure—phenotypes that closely mirror human BS. In addition to model development, Protheragen provides comprehensive characterization services to validate model fidelity, including histological analysis (H&E staining, immunohistochemistry for FOXL2 and PITX2 expression), ophthalmic assessments (slit-lamp biomicroscopy, eyelid measurements, tear film analysis), and molecular profiling (gene expression, protein localization). For in vitro models, we assess cell morphology, proliferation, and function—such as eyelid fibroblast collagen production and lacrimal gland organoid secretion—to ensure they accurately reflect BS pathophysiology. All models are characterized in accordance with GLP standards, ensuring that data generated is reliable and regulatory-compliant.

BS Therapeutic Efficacy Assessment Services

Protheragen offers rigorous therapeutic efficacy assessment services to evaluate the potential of novel drug candidates and therapies for Blepharophimosis Syndrome, using our validated preclinical models. Our services are tailored to the specific therapeutic modality, whether small molecules, gene therapies, therapeutic proteins, or peptides, and include both in vitro and in vivo efficacy testing. For small molecule candidates targeting BS-related pathways (e.g., hedgehog signaling, which is regulated by FOXL2 and critical for eyelid development), we conduct in vitro efficacy assays to assess target modulation, cell function restoration, and reduction of BS-related phenotypes (e.g., abnormal eyelid fibroblast proliferation).

In vivo efficacy testing includes evaluation of ocular phenotypes (palpebral fissure width, ptosis severity, tear production) and systemic manifestations (reproductive organ function) in BS models, using high-resolution imaging and quantitative analysis to measure therapeutic impact. For gene therapy candidates—including AAV-based therapies targeting FOXL2 or PITX2 mutations—Protheragen provides specialized efficacy assessment services, leveraging our expertise in AAV vector technology. Our team evaluates vector transduction efficiency, target gene expression, and phenotypic rescue in BS models, including restoration of eyelid structure, improved lacrimal gland function, and normalization of reproductive hormone levels. We also assess the durability of therapeutic effects over time, providing critical data on long-term efficacy. All efficacy assessments are designed to generate quantitative, reproducible data that can support IND filings, with a focus on endpoints that are clinically relevant to BS, such as improved visual field and prevention of amblyopia.

BS Preclinical Safety and Toxicology Assessment Services

Safety and toxicology assessment is a critical component of preclinical drug development for Blepharophimosis Syndrome, and Protheragen provides comprehensive GLP-compliant safety testing services to evaluate the potential toxic effects of therapeutic candidates. Our services include in vitro toxicology assays (cytotoxicity, genotoxicity, hemocompatibility) using BS-relevant cell models and primary human ocular cells (e.g., corneal epithelial cells, eyelid fibroblasts), to assess the safety of candidates at the cellular level. For in vivo toxicology testing, we use validated animal models to evaluate systemic and ocular toxicity, including assessments of ocular irritation, inflammation, corneal damage, and systemic organ function (liver, kidney, heart, reproductive organs) following administration of the therapeutic candidate.

Protheragen also offers pharmacokinetic (PK) and pharmacodynamic (PD) analysis services to characterize the absorption, distribution, metabolism, and excretion of therapeutic candidates, as well as their dose-response relationships. For gene therapies, we assess vector biodistribution to ensure targeted delivery to ocular and reproductive tissues and minimize off-target effects, and evaluate immune responses to AAV vectors to address potential safety concerns. Our safety and toxicology services are designed to identify potential risks early in preclinical development, allowing clients to optimize their therapeutic candidates and ensure compliance with regulatory requirements for IND filings. By integrating efficacy and safety data, Protheragen provides clients with a comprehensive preclinical data package that supports the transition of BS therapies to clinical trials.

Diagnostics Development

• Karyotype Analysis Service
• Omics Analysis Service
• Biomarker Development Service
• Artificial Intelligence Service

Therapeutic Development

• Small Molecule Drug
• Cell Therapy
• Gene Therapy
• Therapeutic Antibody
• Therapeutic Peptide
• Therapeutic Protein

Preclinical Research

• Pharmacodynamics Study Services
• Pharmacokinetics Study Services
• Drug Safety Evaluation Services

Disease Models

• Foxl2 Knockout Mice with Selective Inactivation in Cranial Neural Crest Cells (CNCCs)
• Foxl2 Knockout Mice with Selective Inactivation in Cranial Mesodermal Cells (CMCs)

Preclinical research services at Protheragen emphasize the exploration of Blepharophimosis Syndrome (BPES) at the molecular level, aiming to uncover potential therapeutic targets. This comprehensive approach encompasses in vitro investigations using patient-derived cells, alongside in vivo models to rigorously assess the efficacy and safety of innovative compounds. If you are interested in our services, please feel free to contact us.

References

• Méjécase, Cécile, et al. "The genetic and clinical features of FOXL2-related blepharophimosis, ptosis and epicanthus inversus syndrome." Genes 12.3 (2021): 364.
• Nuovo, S., et al. "Characterization of endocrine features and genotype–phenotypes correlations in blepharophimosis–ptosis–epicanthus inversus syndrome type 1." Journal of Endocrinological Investigation 39 (2016): 227-233.